Skip to Content

Davide Campari-Milano NV Az nom Post Frazionamento

CPR: XMIL (ITA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€9.00MdysMlllbvxn

Campari Earnings: In Line With Forecasts as Campari Outperforms Larger Competitors

Davide Campari-Milano reported full-year 2023 results in line with our expectations. Top-line growth continues to be strong, and Campari is outperforming its larger peers, including Diageo and Pernod Ricard, thanks to the share gains of its categories. Next year promises to be another year of outperformance, albeit amid an environment of slowing consumer spending. We are reiterating our no-moat rating of Campari and our EUR 9 fair value estimate. With Campari trading around 9% above our valuation as at the close of trading on Feb. 27, we prefer wide-moat-rated Diageo and Pernod Ricard, which both trade at slight discounts to our fair value estimates and have broader portfolios.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CPR so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center